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Introduction
Duchenne muscular dystrophy (DMD) is an X-linked disease caused by mutations in the dystrophin gene leading to the absence of the normal dystrophin protein. The disease has an incidence of 1/4000 -1/5000 male newborns and is caused by a strong destabilisation of the dystrophin associated protein complex at the sarcolemma [1] leading to chronic inflammation, progressive increase of muscle fibrosis and degeneration [2] . DMD patients become wheelchair bound around the age of 12 to 14 [3] and die in their third or fourth decade due to Page 2 of 27 cardiorespiratory failure [4, 5] . The efforts of many laboratories brought new treatments of DMD to the reality, but ongoing and forthcoming clinical trials suffer from absence of valuable biomarkers permitting to follow the treatment results day by day and to correct the treatment if needed. Human urine is one of the major body fluids with relatively stable protein composition, which can be obtained in large quantities using non-invasive procedures [6] . It is considered as an attractive source of biomarkers [7, 8] and several approaches such as 2-DE, MALDI, LC-MS and SELDI have been used to characterise the human urinary proteome [9] [10] [11] . Recently, by using a mass spectrometry approach, we identified fragments of titin as urinary biomarkers offering the possibility to develop a simple, non-invasive and easy-to-use test for the pre-screening of muscular dystrophies including DMD [12] .
In the present study, we used an antibody array approach to prospectively evaluate urine levels of chemokines, cytokines and growth factors in urine from DMD patients and healthy controls. From 274 proteins available for the analysis on the arrays, 128 urinary proteins passed the threshold of assay sensitivity. Surprisingly, statistically significant difference was observed in the level of only one protein, ferritin, which was highly increased in DMD patients compared to healthy controls.
Urinary level of ferritin is extremely low in healthy individuals [13, 14] . High level of urinary ferritin was previously described in patients with chronic haemolytic anaemia as a consequence of glomerular filtration of heme-iron from free haemoglobin [14, 15] . In these patients, the free haemoglobin is actively filtered and catabolized by the kidney thus releasing iron. Liberated iron is then incorporated into the ferritin storage compartment and evacuated from the body when tubular epithelium is shed into the urine [15] . In contrast to urinary ferritin, the serum ferritin level is widely used as an indicator of iron status and its presence in the blood is mainly attributed to a leakage from damaged cells [16] .
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To explain the observed high urinary ferritin content we analysed the levels of iron, iron containing proteins and proteins involved in regulation of iron metabolism in serum and urine of DMD patients and their age matched healthy controls. Obtained data strongly suggest that elevated level of urinary ferritin is functionally linked to the renal management of myoglobin iron derived from leaky muscles of DMD patients. This first observation of the high level of ferritin in urine of DMD patients shed light on the mechanisms of iron metabolism and kidney functioning in DMD.
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Materials and Methods
Human Sample Collection
The study was conducted as part of ADNA (Avancées Diagnostiques pour de Nouvelles Approches thérapeutiques) project according to the principles of the declaration of Helsinki "Ethical Principles for Medical Research Involving Human Subjects". The study protocol and Informed Consent was approved by the Institutional Review Board (IRB) and Informed Consent was obtained from all subjects prior to the study.
Samples from DMD patients and from age and sex-matched healthy control subjects were collected at the Cincinnati Children's Hospital Medical Center, USA. For all patients, DMD was diagnosed on the basis of genetic testing (Supplementary Table 1 ). Subjects with a known medical disorder, mental retardation or autistic/pervasive developmental disorders as well as intercurrent illness (infections, cold or fever) or elevated CRPs were not included in the study.
Blood of DMD patients and healthy controls was collected in dry tubes (BD Vacutainer, # 367815) and samples were allowed to clot at room temperature for 20 min. After10 min of centrifugation at 2,000 g serum was collected and stored at -80°C. Urine samples were centrifuged immediately after collection (1800g, 10 min, 4°C) and supernatants were stored at -80°C. Before use, urine samples were concentrated 10 times using Amicon Ultra-15
Centrifugal Filter Units (cut-off 3 kDa, Millipore) following the manufacturer's instructions.
Protein quantification
Protein concentration was determined using the Bio-Rad Protein Assay Dye Reagent (BioRad) according to the manufacturer's instructions with bovine serum albumin as a standard. 
Antibody Arrays
ELISA
Urine and serum levels of ferritin in DMD patients and healthy controls were determined by commercial ELISA kits (ELH-Ferritin, RayBiotech). After determination of optimal sample dilutions, all assays were performed according to the manufacturer's instructions. Liquid chromatography-tandem mass spectrometry assay of hepcidin levels.
Biochemical and clinical parameters
Hepcidin levels were measured by a liquid chromatography-tandem mass spectrometry method [17, 18] after solid phase extraction of serum samples.
Determination of serum and urinary iron by Inductively Coupled Plasma Mass
Spectrometry (ICP-MS)
In serum total iron was determined by an assay developed by [19] adopted to automatic measurement on Dimension Vista analyser system (Siemens).
Urinary iron was quantified by Inductively Coupled Plasma Mass Spectrometry (ICP-MS).
200 μL of urine stored at −80°C were used for quantification. Elemental analyses were performed using inductively coupled plasma mass spectrometry (ICP-MS; Varian® 820-MS) with a collision/reaction cell system autosampler (SPS3, Varian®). The system was operated at a radio frequency power of 1550 W with an argon plasma gas flow rate of 15 L/min.
Standard solutions for the external calibrations (VWR International, Leuven, Belgium) and internal standards (Yttrium ICP Standard; Merck, Darmstadt, Germany) were prepared freshly before every run in 20% nitric acid. Iron was measured in reaction cell mode using H 2 gas 
Statistical analysis
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Statistical analyses were performed using the GraphPad Prism version 6.04. Data are expressed as mean ± SEM if not otherwise specified. For comparisons between means, homogeneity of variances was assessed by Fisher-Snedecor's test and the Student's t-test (two-tailed) was applied. Pearson's correlation was used for correlation studies and data were analysed with a 95% confidence interval and P < 0.05 was considered significant.
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Results
Detection of differentially present proteins in urine by antibody array analysis
For this analysis, urine samples from DMD patients and age and sex-matched healthy control subjects were organized in a total of 12 pools according to the patient's age (Table 1) 
Individual analysis of ferritin
In order to confirm the differences in ferritin levels and to estimate its individual variability, urinary ferritin was analysed by ELISA in each subject of the entire cohorts (34 DMD patients from 3 to 10 years old versus 25 age matched controls; 12 DMD patients from 12 to 20 years old versus 20 age matched controls). The results of the ELISA assay completely corroborate the data obtained by antibody arrays: ferritin level in young DMD patients was significantly higher than in healthy controls (251 ng/ml ± 30 versus 4.5 ng/ml ± 0.7, p-value<0.001). Level of urinary ferritin decreased with age of DMD patients remaining 10 times higher than in the healthy controls (70 ng/ml ± 19 versus 7.2 ng/ml ± 2, p-value<0.01) (Figure 2 ).
In order to confirm high ferritin content in urine of DMD patients, we performed urinary ferritin analysis in an independent cohort of 47 DMD patients and 72 healthy control subjects collected in several specialised centres located in France, Belgium, and Romania. Data 
Urinary ferritin and iron metabolism
Next we asked the question if urinary protein was excreted in the form of ferritin (bound with iron) or in the form of apoferritin (not combined with iron). Concentration of urinary iron was significantly higher in young DMD patients compared to age-matched healthy controls (0.62 µmol/L ± 0.09 versus 0.15 µmol/L ± 0.03 respectively, p-value<0.001) and furthermore, urinary iron tightly correlated with urinary ferritin (R=0.76). To confirm that urinary iron is bound to ferritin, co-elution of ferritin and iron was monitored after urine fractionation by gel filtration chromatography (Figure 3 ). All ferritin was eluted in the first fractions To find the origin of urinary ferritin, we quantified its levels in serum. Surprisingly, in young DMD patients, urinary ferritin (251 ng/ml ± 30) exceeded nearly 10 times its serum level (28 ng/ml ± 2.8) while in healthy individuals concentration of ferritin was higher in serum compared to urine (28.4 ng/ml ± 2.3 versus 4.5 ng/ml ± 0.7). Moreover, despite the significant increase of urinary ferritin in DMD patients, serum parameters reflecting iron status: serum ferritin, serum iron, serum transferrin, transferrin saturation, soluble transferrin receptor, serum hepcidin and total iron binding capacity were within the normal reference ranges ( Table 2) .
Origin of urinary ferritin and iron in DMD patients
Increased urinary iron and ferritin were already described in haemolytic anaemia and in animal models of haem-induced injury as a consequence of glomerular filtration of heme-iron from free haemoglobin. In such cases, haemolytic syndromes were associated with a dysregulation of iron metabolism [15, 24] . However, no significant difference was observed in parameters reflecting either iron metabolism or haemolysis between DMD patients and healthy controls in the studies cohort ( Table 2) . Serum haptoglobin and hemopexin were within the normal range. These results prompted us to hypothesize that another heme-iron carrier protein, myoglobin, is the source of increased urinary iron and ferritin levels in DMD patients. Indeed, in accordance with previously published data [25, 26] 
Evaluation of renal function in DMD patients
Lifelong arrival of myoglobin to the renal cells produces chronic excess of heme-iron which could be deleterious for kidney functions. To assess renal function in DMD patients, we estimated the glomerular filtration rate (eGFR) based on the serum level of cystatin-C.
Cystatin-C was chosen because its level is less affected by muscle mass compared to conventional serum creatinine [21] . The eGFR was calculated based on the cystatin-C Filler equation [20] , which is the closest estimation of the measured GFR in DMD patients [22] . In young DMD patients eGFR was not significantly different from respective healthy controls (Table 3) . In accordance with published data [7] , eGFR decreased in older healthy controls.
Intriguingly, eGFR was significantly higher in older DMD patients than in respective healthy controls ( Table 3) . This increase in eGFR value indicates on a moderate hyperfiltration in older DMD patients that could reflect first signs of kidney dysfunction.
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Discussion
In the present study the level of 128 urinary proteins including growth factors, cytokines and chemokines were compared in urine of DMD patients and age related control subjects by antibody array approach. Surprisingly, statistically significant difference was observed only for urinary ferritin whose level was at least ten times higher in DMD patients.
Ferritin is a 24 subunits cytosolic protein composed of two chains: heavy chain (H-ferritin) and light chain (L-ferritin) which forma structure that can store up to 4500 iron ions in a nontoxic form. The H-ferritin possesses the ferroxidase activity transforming the ferrous ions Fe(II) into ferric ions Fe(III). The ferric ions are then translocated into the core of the ferritin shell where L-ferritin assists in iron mineralization thus protecting cells against free iron related production of reactive oxygen species (For review see [27] ).
Ferritinuria was previously described in patients suffering from chronic haemolytic anaemia [14] . Under this condition, when free haemoglobin exceeds the haptoglobin binding capacity, the excess is filtered by the kidney [8] . In renal cells, the iron liberated from haemoglobin induces ferritin production [10] which sequesters iron and prevents iron related damage. The authors proposed that the high level of urinary ferritin was the result of the shedding of tubular epithelium into the urine [14] . In DMD patients, there is no evidence that erythrocytes have survival defects [9] . In the absence of inflammation and taking into account that all tested parameters reflecting serum iron and haemolysis status in the studies cohort were within the normal reference ranges it is reasonable to suggest that the turnover of another heme-carrier protein, myoglobin, is the reason for the increased urinary iron and ferritin in DMD patients.Indeed, increased level of myoglobin was already described in serum of DMD patients as a result of muscle leakage [11, 28] . Moderate but significant correlations between serum myoglobin and urinary ferritin as well as between serum myoglobin and urinary iron supported myoglobin metabolism as a cause of increased urinary iron and ferritin. It is highly possible that correlations between serum myoglobin and urinary ferritin/iron are impacted by the long-time retention of ferritin in renal cells before being shed into the urine [29] . Because urines in the present study were obtained at the time of patient visit (midstream urines), the retention of ferritin (and iron) in kidney could lessen the correlation between serum myoglobin and urinary ferritin/iron. It is also possible that part of serum myoglobin was cleared by the liver [30, 31] , but this process is difficult to quantify since hepatic clearance is highly variable [32] .
In renal cells, iron released from myoglobin could provoke oxidative damage and induce kidney failure as in the case of acute rhabdomyolysis [33] . Recently, Zorova and colleagues demonstrated the importance of the activation of myoglobin and heme degradation by heme oxygenase for the reduction of renal damage and renal failure associated with rhabdomyolysis [34] . Importantly, temporary and acute increase of serum myoglobin up to 4 mg/L [35] or even 15 mg/L [36] can be tolerated by the kidney without clear renal manifestation. In our cohort, the mean level of serum myoglobin in young DMD patients was 2 mg/L, but contrary to acute rhabdomyolysis event where myoglobin is quickly eliminated from the serum [37] , DMD patients suffer from chronic muscle leakage and a lifelong presence of serum myoglobin. This lifelong serum myoglobin persistence and concomitant iron renal recycling could be deleterious for patient's kidneys in the long term. The evaluation of the GFR in DMD patients and healthy subjects demonstrated no kidney function impairment in young DMD patients. However, we observed statistically significant increase of eGFR in older DMD patients indicating on a moderate glomerular hyperfiltration. Hyperfiltration was suggested as an early marker of renal damage in pre-diabetes and pre-hypertension [38] , and it may be the first sign of progressive loss of kidney function in diabetes, cancer or obesity (for review see [39] ). Importantly, hyperfiltration was already reported in DMD patients [22] and kidney failure was observed in older DMD patients [40, 41] . The presence of kidney injury Page 15 of 27 was also described in the mdx mouse [42] . Many factors including dehydration, use of high doses of diuretics or fluid intake reduction are known to accelerate renal failure in DMD patients [40, 41] . Our results indicate that modified renal iron metabolism could be a component of kidney failure process. Extension of patients' life with coming in age new therapeutics [43] [44] [45] [46] Table 2 .
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